Skip to main content

Advertisement

SpringerLink
Log in

Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel

Part 1: Definitions, Assessments, Education, and Future Directions

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rockson SG. Update on the biology and treatment of lymphedema. Curr Treat Options Cardiovasc Med. 2012;14:184–92.

    Article  PubMed  Google Scholar 

  2. Shih YC, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14.

    Article  PubMed  Google Scholar 

  3. Basta MN, et al. Complicated breast cancer-related lymphedema: evaluating health care resource utilization and associated costs of management. Am J Surg. 2016;211:133–41.

    Article  PubMed  Google Scholar 

  4. Boyages J, et al. Worse and worse off: the impact of lymphedema on work and career after breast cancer. SpringerPlus. 2016;5:657.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ververs JM, et al. Risk, severity, and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer. 2001;37:991–9.

    Article  CAS  PubMed  Google Scholar 

  6. Shaitelman SF, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015;65:55–81.

    Article  PubMed  Google Scholar 

  7. The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology. 2016;49:170–84.

    Google Scholar 

  8. Armer JM, et al. Best Practice Guidelines in Assessment, Risk Reduction, Management, and Surveillance for Post-Breast Cancer Lymphedema. Curr Breast Cancer Rep. 2013;5:134–44.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ostby PL, et al. Surveillance recommendations in reducing risk of and optimally managing breast cancer-related lymphedema. J Person Med. 2014;4:424–47.

    Article  Google Scholar 

  10. Perdomo M, Levenhagen K, Ryans K. Breast Cancer EDGE Task Force Outcomes: Assessment measures of secondary lymphedema in breast cancer survivors. Rehabil Oncol. 2014;32:22–35.

    Google Scholar 

  11. NLNMA, C. Supplement to the NLN position breast cancer screening: screening and early detection of breast cancer-related lymphedema. The Imperative. National Lymphedema Network, 2012.

    Google Scholar 

  12. Commitee, NLNMA. Supplement to the NLN position breast cancer screening: screening and early detection of breast cancer -related lymphedema. The Imperative, 2012, National Lymphedema Network.

    Google Scholar 

  13. Armer JM. The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest. 2005;23:76–83.

    Article  PubMed  Google Scholar 

  14. Olszewski WL (1991) Volumetry of limbs, in Pathophysiology, Diagnosis, and Treatment. CRC Press, Boston pp. 444–51.

    Google Scholar 

  15. Gerber LH. A review of measures of lymphedema. Cancer. 1998;83(12 Suppl):2803–14.

    Article  CAS  PubMed  Google Scholar 

  16. Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010;43:118–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Taylor R, et al. Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther. 2006;86:205–14.

    PubMed  Google Scholar 

  18. Stout Gergich NL, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008;112:2809–19.

    Article  PubMed  Google Scholar 

  19. Johansson K, Branje E. Arm lymphoedema in a cohort of breast cancer survivors 10 years after diagnosis. Acta Oncol. 2010;49:166–73.

    Article  PubMed  Google Scholar 

  20. Bar Ad V, et al. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2010;76:85–90.

    Article  Google Scholar 

  21. Torres Lacomba M, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010;340:b5396.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lahtinen T, et al. Experimental and analytical comparisons of tissue dielectric constant (TDC) and bioimpedance spectroscopy (BIS) in assessment of early arm lymphedema in breast cancer patients after axillary surgery and radiotherapy. Lymphatic Res Biol. 2015;13:176–85.

    Article  Google Scholar 

  23. Stout NL, et al. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther. 2012;92:152–63.

    Article  PubMed  Google Scholar 

  24. C, S. Multifrequency bioimpedance in the early detection of lymphoedema after axillary surgery: an observational cohort study, 2015. Retrieved 16 June 2017 http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN48880939.

  25. Ridner S. A randomized trial evaluating bioimpedance spectroscopy versus tape measurement in the prevention of lymphedema following locoregional treatment for breast cancer, 2014 Retrieved 16 June 2016 https://clinicaltrials.gov/ct2/show/NCT02167659.

  26. Kilbreath SL, et al. Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer. 2013;21:2207–15.

    Article  PubMed  Google Scholar 

  27. Laidley A, Anglin B. The impact of L-Dex((R)) measurements in assessing breast cancer-related lymphedema as part of routine clinical practice. Frontiers Oncol. 2016;6:192.

    Article  Google Scholar 

  28. Specht MC, et al. Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression? Breast Cancer Res Treat. 2013;140:485–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. National Lymphedema Network, July 2012. Retrieved 4 March 2017 www.lymphnet.org.

  30. Armer JM, et al. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res. 2003;52:370–9.

    Article  PubMed  Google Scholar 

  31. Teo I, et al. Examining pain, body image, and depressive symptoms in patients with lymphedema secondary to breast cancer. Psycho-oncology. 2015;24:1377–83.

    Article  PubMed  Google Scholar 

  32. Sackey H, et al. Self-perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery. Eur J Surg Oncol. 2015;41:577–84.

    Article  CAS  PubMed  Google Scholar 

  33. Bulley C, et al. Comparison of breast cancer-related lymphedema (upper limb swelling) prevalence estimated using objective and subjective criteria and relationship with quality of life. BioMed Res Int. 2013;2013:807569.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Radina E, et al. Self-reported management of breast cancer-related lymphoedema. J Lymphoedema. 2007;2:12–21.

    PubMed  PubMed Central  Google Scholar 

  35. Ridner SH, Dietrich MS, Kidd N. Breast cancer treatment-related lymphedema self-care: education, practices, symptoms, and quality of life. Support Care Cancer. 2011;19:631–7.

    Article  PubMed  Google Scholar 

  36. Hayes SC, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49.

    Article  PubMed  Google Scholar 

  37. Pusic AL, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Survivorship Res Pract. 2013;7:83–92.

    Article  Google Scholar 

  38. Brach M, et al. ICF core sets for breast cancer. J Rehabil Med. 2004; 36(44 Suppl):121–127.

    Article  Google Scholar 

  39. Devoogdt N, et al. Lymphoedema functioning, disability, and health questionnaire (Lymph-ICF): reliability and validity. Phys Ther. 2011;91:944–57.

    Article  PubMed  Google Scholar 

  40. Ridner SH, Dietrich MS. Development and validation of the lymphedema symptom and intensity survey arm. Support Care Cancer. 2015;23:3103–12.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Bulley C, et al. A morbidity screening tool for identifying fatigue, pain, upper limb dysfunction, and lymphedema after breast cancer treatment: a validity study. Eur J Oncol Nurs. 2014;18:218–27.

    Article  PubMed  Google Scholar 

  42. Fu MR, et al. Symptom report in detecting breast cancer-related lymphedema. Breast Cancer. 2015;7:345–52.

    PubMed  PubMed Central  Google Scholar 

  43. National Comprehensive Cancer Network (NCCN) Guideline Version 2.2016, 2016. Retrieved 23 January 2017 at http://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf .

  44. Blaney JM, et al. Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures. Support Care Cancer. 2015;23:1549–59.

    Article  CAS  PubMed  Google Scholar 

  45. Czerniec SA, et al. Assessment of breast cancer-related arm lymphedema: comparison of physical measurement methods and self-report. Cancer Invest. 2010;28:54–62.

    Article  CAS  PubMed  Google Scholar 

  46. Gartner R, et al. Self-reported arm-lymphedema and functional impairment after breast cancer treatment: a nationwide study of prevalence and associated factors. Breast. 2010;19:506–15.

    Article  PubMed  Google Scholar 

  47. Coster S, Poole K, Fallowfield LJ. The validation of a quality-of-life scale to assess the impact of arm morbidity in breast cancer patients postoperatively. Breast Cancer Res Treat. 2001;68:273–82.

    Article  CAS  PubMed  Google Scholar 

  48. Keeley V, C.S., Locke J, Viegas D. A quality-of-life measure for limb lymphedema (LYMQOL). J Lymphoedem. 2010;5:26–37.

  49. Weiss J, Daniel T. Validation of the Lymphedema Life Impact Scale (Llis): a condition-specific measurement tool for persons with lymphedema. Lymphology. 2015;48:128–38.

    CAS  PubMed  Google Scholar 

  50. Ozcinar B, et al. Breast cancer-related lymphedema in patients with different locoregional treatments. Breast. 2012;21:361–5.

    Article  PubMed  Google Scholar 

  51. Nesvold IL, et al. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol. 2008;47:835–42.

    Article  PubMed  Google Scholar 

  52. Ashikaga T, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111–8.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wernicke AG, et al. A 10-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance. Breast Cancer Res. Treat. 2011;125:893–902.

    Article  PubMed  Google Scholar 

  54. Swaroop MN, et al. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat. 2015;151:393–403.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Viera RA, de Souza JL, et al. Risk factors for arm lymphedema in a cohort of breast cancer patients followed for 10 years. Breast Cancer Basel. 2016;11:45–50.

    Google Scholar 

  56. Vicini F, et al. Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. Clin Breast Cancer. 2012;12:133–7.

    Article  PubMed  Google Scholar 

  57. Coen JJ, et al. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1209–15.

    Article  PubMed  Google Scholar 

  58. Hayes SB, et al. Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation? Int J Radiat Oncol Biol Phys. 2008;72:1449–55.

    Article  PubMed  Google Scholar 

  59. Kim M, et al. Identification of prognostic risk factors for transient and persistent lymphedema after multimodal treatment for breast cancer. Cancer Res Treat. 2016;48:1330–7.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kilbreath SL, et al. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast. 2016;28:29–36.

    Article  CAS  PubMed  Google Scholar 

  61. Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 noninferiority trial. Lancet Oncol. 2014;15:1303–10.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Cariati M, et al. Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. Br J Surg. 2015;102:1071–8.

    Article  CAS  PubMed  Google Scholar 

  63. Kwan ML, et al. Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010;145:1055–63.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Norman SA, et al. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev. 2010;19:2734–46.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Wetzig N, et al, Sentinel-lymph-node-based management or routine axillary clearance? Five-year outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: assessment and incidence of true lymphedema. Ann Surg Oncol. 2017;24:1064–70.

    Article  PubMed  Google Scholar 

  66. Rebegea L, et al. The incidence and risk factors for occurrence of arm lymphedema after treatment of breast cancer. Chirurgia. 2015;110:33–7.

    CAS  PubMed  Google Scholar 

  67. Ridner SH, Dietrich MS. Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum. 2008;35:57–63.

    Article  PubMed  Google Scholar 

  68. Deutsch M, et al. The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys. 2008;70:1020–4.

    Article  PubMed  Google Scholar 

  69. Fu MR. Breast cancer-related lymphedema: symptoms, diagnosis, risk reduction, and management. World J Clin Oncol. 2014;5:241–7.

    Article  PubMed  PubMed Central  Google Scholar 

  70. McLaughlin SA, et al. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2012; 216:380–389.

    Article  PubMed  Google Scholar 

  71. Shah C, et al. The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. Cancer Med. 2016;5:1154–62.

    Article  PubMed  PubMed Central  Google Scholar 

  72. DiSipio T, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500–15.

    Article  PubMed  Google Scholar 

  73. Helyer LK, et al. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010;16:48–54.

    Article  PubMed  Google Scholar 

  74. Boccardo FM, et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology. 2009;42:1–9.

    CAS  PubMed  Google Scholar 

  75. Norman SA, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27:390–7.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Ugur S, et al. Risk factors of breast cancer-related lymphedema. Lymphat Res Biol. 2013;11:72–5.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Lu SR, et al. Role of physiotherapy and patient education in lymphedema control following breast cancer surgery. Therapeut Clin Risk Manage. 2015;11:319–27.

    Google Scholar 

  78. Basen-Enquist K, T.C., Rosenblum C, Smith MA, Shinn EH, Greisinger A. Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient Educ Couns. 2016;64:225–34.

    Article  Google Scholar 

  79. Szuba A, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;16:1985–7.

    CAS  PubMed  Google Scholar 

  80. Yoon YS, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003;111:717–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Jin DP, et al. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. Lymphat Res Biol. 2009;7:47–57.

    Article  CAS  PubMed  Google Scholar 

  82. Tammela T, et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med. 2007;13:1458–66.

    Article  CAS  PubMed  Google Scholar 

  83. Norrmen C, et al. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011;123:1335–51.

    Article  PubMed  Google Scholar 

  84. Saaristo A, et al. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J. 2004;18:1707–9.

    CAS  PubMed  Google Scholar 

  85. Goldman J, et al. Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin. Circ Res. 2005;96:1193–9.

    Article  CAS  PubMed  Google Scholar 

  86. Qi S, Pan J. Cell-based therapy for therapeutic lymphangiogenesis. Stem Cells Develop. 2015;24:271–83.

    Article  Google Scholar 

  87. Yan A, et al. Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-beta1 inhibition. Future Oncol. 2011;7:1457–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Shimizu Y, Shibata S.R, Shintani S, Ishii M, Murohara T. Therapeutic lymphangiogenesis with implantation of adipose-derived regenerative cells. J Am Heart Assoc. 2012; 1:e000877.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Ackermann M, Senaldi C, Kalbermatten D, Konerding M, Raffoul W, Erba P, Impact of platelet rich plasma and adipose stem cells on lymphangiogenesis in a murine tail lymphedema model. Microvasc Res. 2015;102:78–85.

    Article  PubMed  Google Scholar 

  90. Chen HC, et al. Lymph node transfer for the treatment of obstructive lymphoedema in the canine model. Br J Plast Surg. 1990;43:578–86.

    Article  CAS  PubMed  Google Scholar 

  91. Becker C, et al. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg. 2006;243:313–5.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Lahteenvuo M, et al. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation. 2011;123:613–20.

    Article  PubMed  CAS  Google Scholar 

  93. Hadamitzky C, et al. Aligned nanofibrillar collagen scaffolds: guiding lymphangiogenesis for treatment of acquired lymphedema. Biomaterials. 2016;102:259–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Huang NF, et al. The modulation of endothelial cell morphology, function, and survival using anisotropic nanofibrillar collagen scaffolds. Biomaterials. 2013;34:4038–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Badger C, et al. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database System Rev. 2004; 2:CD003140.

    Google Scholar 

  96. Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol. 2008;52:799–806.

    Article  PubMed  Google Scholar 

  97. Tabibiazar R, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3:e254.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Tabibiazar R, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3:e254.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Nakamura K, et al. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PloS One. 2009;4:e8380.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Tian W, et al. Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Translat Med. 2017; 9(389):eaal3920.

    Article  Google Scholar 

  101. Whelan TJ, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Olson JA Jr, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol. 2008;26:3530–5.

    Article  PubMed  Google Scholar 

  103. Wilke LG, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.

    Article  PubMed  Google Scholar 

  104. Lucci A, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–63.

    Article  PubMed  Google Scholar 

  105. Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Choi YH, Seo KS. Correlation among bioimpedance analysis, sonographic and circumferential measurement in assessment of breast cancer-related arm lymphedema. Lymphology. 2014;47:123–33.

    CAS  PubMed  Google Scholar 

  107. Devoogdt N, et al. Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedema. Lymphat Res Biol. 2014;12:23–31.

    Article  PubMed  Google Scholar 

  108. Hwang JH, et al. A new soft tissue volume measurement strategy using ultrasonography. Lymphat Res Biol. 2014;12:89–94.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Johnson KC, et al. Ultrasound and clinical measures for lymphedema. Lymphat Res Biol. 2016;14:8–17.

    Article  PubMed  Google Scholar 

  110. Mayrovitz HN, Weingrad DN, Lopez L. Patterns of temporal changes in tissue dielectric constant as indices of localized skin water changes in women treated for breast cancer: a pilot study. Lymphat Res Biol. 2015;13:20–32.

    Article  PubMed  Google Scholar 

  111. Mellor RH, et al. Dual-frequency ultrasound examination of skin and subcutis thickness in breast cancer-related lymphedema. Breast J. 2004;10:496–503.

    Article  PubMed  Google Scholar 

  112. Suehiro K, et al. Skin and subcutaneous tissue ultrasonography features in breast cancer-related lymphedema. Ann Vasc Dis. 2016;9:312–6.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was funded via an unrestricted educational Grant from ImpediMed.

Disclosure

Frank Vicini is a research adviser for ImpediMed. Sarah A. McLaughlin, Alicia C. Staley, Paul Thiruchelvam, Nancy A. Hutchison, Jane Mendez, Fiona MacNeill, Stanley G. Rockson, Sarah M. DeSnyder, Suzanne Klimberg, Michael Alatriste, Francesco Boccardo, Mark L Smith, and Sheldon M. Feldman have no conflicts of interest to report.

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic, Jacksonville, FL, USA

    Sarah A. McLaughlin MD

  2. Patient Advocate, Akari Health, Boston, MA, USA

    Alicia C. Staley MBA, MS, BS

  3. Radiation Oncology, UCLA School of Medicine, Los Angeles, USA

    Frank Vicini MD, FACR, FABS

  4. Imperial College Healthcare, London, UK

    Paul Thiruchelvam BSc, MD, PhD, FRCS

  5. Courage Kenny Rehabilitation Institute of AllinaHealth, Minneapolis, MN, USA

    Nancy A. Hutchison MD, CLT-LANA

  6. Miami Cancer Institute, Miami, FL, USA

    Jane Mendez MD

  7. Association of Breast Surgery Great Britain and Ireland, Royal College of Surgeons of England, London, UK

    Fiona MacNeill FRCS, MD, FEBS

  8. Center for Lymphatic and Venous Disorders, Stanford University School of Medicine, Stanford, CA, USA

    Stanley G. Rockson MD

  9. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Sarah M. DeSnyder MD

  10. Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, USA

    Suzanne Klimberg MD, PhD

  11. Lymphedema Alliance of New York, New York, NY, USA

    Michael Alatriste LMT, CLT

  12. Department of Surgery, Unit of Lymphatic Surgery - S. Martino University Hospital, University of Genoa, Genoa, Italy

    Francesco Boccardo MD, PhD, FACS

  13. Hofstra Northwell School of Medicine, Northwell Health Cancer Institute, Lake Success, NY, USA

    Mark L. Smith MD, FACS

  14. Division of Breast Surgery and Breast Surgical Oncology, Department of Surgery, Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, New York, NY, USA

    Sheldon M. Feldman MD, FACS

Authors
  1. Sarah A. McLaughlin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia C. Staley MBA, MS, BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Vicini MD, FACR, FABS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Thiruchelvam BSc, MD, PhD, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nancy A. Hutchison MD, CLT-LANA
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jane Mendez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fiona MacNeill FRCS, MD, FEBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Stanley G. Rockson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sarah M. DeSnyder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Suzanne Klimberg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michael Alatriste LMT, CLT
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Francesco Boccardo MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mark L. Smith MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sheldon M. Feldman MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah A. McLaughlin MD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 61 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McLaughlin, S.A., Staley, A.C., Vicini, F. et al. Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel. Ann Surg Oncol 24, 2818–2826 (2017). https://doi.org/10.1245/s10434-017-5982-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-5982-4

Keywords

Search

Navigation